Quote:

---

The fees have soared since the program’s inception three decades ago and now make up nearly half of the F.D.A.’s budget, financing 6,500 jobs at the agency.

---

Hey, gotta keep the barriers against emerging pre-revenue biotechs with innovative, superior-to-Big-Pharma treatments as high as possible, right?

The last thing on earth the FDA wants is for BP revenue streams to get cut off and to have the masses actually get cured instead of being their perpetual customers.